<p>AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.</p>.<p>Patients showed a statistically significant improvement when two fixed doses of the drug, tavapadon, as a monotherapy were compared to placebo, as measured on a rating scale.</p>.<p>The Movement Disorder Society - Unified Parkinson's Disease Rating Scale was developed to evaluate various aspects of Parkinson's disease.</p>.<p>The trial enrolled 529 adults between the ages of 40 and 80, who had the disease for less than three years.</p>.<p>The drug also met the secondary goal by showing improvement in motor skills required for daily activities in both 5 mg and 15 mg doses at 26 weeks.</p>.<p>AbbVie gained access to the treatment with its $8.7 billion buyout of Cerevel Therapeutics.</p>.<p>Tavapadon is being studied as a once-daily treatment for Parkinson's disease, a nervous system disorder that causes progressive brain damage leading to symptoms that include problems with movement, tremor, stiffness, and impaired balance.</p>.<p>In another late-stage trial, tavapadon improved symptom control in patients when tested as an add-on therapy to levodopa, the standard of care of the disease.</p>.<p>Results from another late-stage trial, studying tavapadon as a flexible-dose monotherapy, is expected by the end of the year, AbbVie said. </p>
<p>AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.</p>.<p>Patients showed a statistically significant improvement when two fixed doses of the drug, tavapadon, as a monotherapy were compared to placebo, as measured on a rating scale.</p>.<p>The Movement Disorder Society - Unified Parkinson's Disease Rating Scale was developed to evaluate various aspects of Parkinson's disease.</p>.<p>The trial enrolled 529 adults between the ages of 40 and 80, who had the disease for less than three years.</p>.<p>The drug also met the secondary goal by showing improvement in motor skills required for daily activities in both 5 mg and 15 mg doses at 26 weeks.</p>.<p>AbbVie gained access to the treatment with its $8.7 billion buyout of Cerevel Therapeutics.</p>.<p>Tavapadon is being studied as a once-daily treatment for Parkinson's disease, a nervous system disorder that causes progressive brain damage leading to symptoms that include problems with movement, tremor, stiffness, and impaired balance.</p>.<p>In another late-stage trial, tavapadon improved symptom control in patients when tested as an add-on therapy to levodopa, the standard of care of the disease.</p>.<p>Results from another late-stage trial, studying tavapadon as a flexible-dose monotherapy, is expected by the end of the year, AbbVie said. </p>